Reader sentiment, not investment advice. One vote per visitor; click again to change it.
VERA last changed hands at $29.83 (down 1.94%). At $2.15B, Vera Therapeutics is ranked #2721 by size among the 3132 stocks on BeStock.
Over a full year the shares have ranged across $23.05 to $56.05, which puts the current price roughly 21% of the way up that band.
For the quarter ended Jun 2026 it reported $0.00 in revenue, and a net loss of $109.47M.
11 analysts follow the stock and the average call is "buy". The mean target, $77.22, sits 158.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
11 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
VERA is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $77.22, 158.9% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $45.65, so shares trade 34.7% below that estimate. On earnings multiple, it sits in the 74th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$29.83 is the latest print for VERA, a move of -1.94% against yesterday's close of $30.42. Today's low and high so far: $28.79 and $30.74.
Equity value comes to $2.15B at the current price. By that measure it is number 2721 of the 3132 names in our coverage.
The year's floor is $23.05 and the ceiling $56.05. Shares are 46.8% away from that ceiling.
Our data shows no dividend paid by Vera Therapeutics over the trailing twelve months.
Of 11 analysts, 91% say buy, 9% hold and 0% sell. Price targets average $77.22, with the most cautious at $34.00 and the most optimistic at $100.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on VERA.